VIP (Vasoactive Intestinal Peptide): Research Overview

Vasoactive Intestinal Peptide, or VIP, is a 28-amino-acid neuropeptide found in human physiology. It was identified in the early 1970s and has since been described as a signaling molecule with effects across the gut, lungs, immune system, brain, and blood vessels. Research sources describe VIP as a broad regulator, not a single-purpose peptide.

• VIP is a 28-amino-acid neuropeptide with wide effects across several organ systems.
• It is linked to immune balance, gut function, airway tone, and circadian signaling.
• Research sources describe VIP as anti-inflammatory and immunomodulatory, with effects on cytokines and regulatory T cells.
• Low VIP signaling has been reported in chronic inflammatory states, including chronic inflammatory response syndrome linked to water-damaged buildings.

What VIP Is

VIP stands for Vasoactive Intestinal Peptide. It is also called vasoactive intestinal polypeptide in some sources. It is a naturally occurring neuropeptide, meaning it acts as a messenger in the nervous system and in other tissues. One source describes it as part of the glucagon/secretin superfamily. Another notes that it is produced in neurons throughout the enteric nervous system, the central and peripheral nervous systems, and the lungs.

That wide distribution matters. VIP is not limited to one organ. It acts as a systems-level signal. The research materials describe it as a coordinator of how tissues respond to stress, inflammation, and injury. It is present in the gut, the lungs, the brain, immune cells, and vascular tissue.

Why researchers pay attention to it

VIP is often discussed because it appears to sit at the meeting point of the neuro-immune-gut axis. In the materials provided, it is linked to immune tolerance, inflammatory control, autonomic regulation, epithelial integrity, bronchodilation, and circadian rhythm. That gives it a much wider profile than peptides with one main job.

How VIP Works

VIP signals through two main receptors: VPAC1 and VPAC2. The research sources say these receptors are widely expressed, including in the hypothalamus, lung, small intestine, immune cells, pituitary gland, and vascular smooth muscle. Because of that spread, VIP can affect several systems at once.

One source notes that VIP raises cAMP after receptor activation. Another says that in healthy volunteers, IV infusion of VIP raised plasma levels quickly, with a half-time of disappearance of about one minute after the infusion stopped. In that human study, higher doses were associated with small but significant increases in glucose, free fatty acids, calcium, pulse rate, and blood pressure amplitude, along with cutaneous flushing.

That same study also stated that the findings did not support VIP as a circulating hormone under normal physiological conditions. Instead, it fits better as a local and neural signaling molecule.

System-level signaling

Because VIP receptors are found in so many tissues, VIP can influence smooth muscle, immune cells, gut lining, airway tone, and the hypothalamic-pituitary axis. One source says this includes support for MSH production through hypothalamic POMC processing. Another says VIP helps regulate circadian rhythm entrainment through neurons in the suprachiasmatic nucleus.

For a related example of a peptide with broad physiologic reach, see LL37. For another endogenous signaling peptide often discussed in physiology, see Oxytocin.

Immune Balance and Inflammation

The clearest theme in the research is VIP’s immune role. The sources describe it as one of the most potent anti-inflammatory neuropeptides in the body. It is linked to suppression of inflammatory signaling and support for immune tolerance.

Specific immune effects named in the materials include suppression of pro-inflammatory cytokines such as TNF-alpha, IL-6, and IL-12, and promotion of anti-inflammatory cytokines such as IL-10. The sources also describe increased regulatory T-cell activity and reduced excessive Th1 and Th17 responses.

One clinic reference says VIP suppresses NF-kB activation in immune cells and downstream production of IL-6, TNF-alpha, IL-12, and MMP-9, while promoting IL-10 and TGF-beta1 regulatory signaling. Taken together, the materials present VIP as a peptide with strong immune-calming effects.

Why this matters

Inflammation is useful when it is brief and targeted. It becomes a problem when it stays active too long or becomes poorly controlled. The provided research frames VIP as part of the body’s brake system. In that model, low or dysfunctional VIP signaling may allow inflammation to continue longer than it should.

That idea is central to the sources that discuss chronic inflammatory illness. They do not say VIP is the only factor. They do say it may be an important part of immune balance.

Gut, Lung, and Blood Vessel Effects

VIP first drew attention because of its gut effects, but the research shows a wider pattern. The gut, airways, and blood vessels all appear in the source material.

Gut function

The gut-related materials describe VIP as part of the enteric nervous system and as a regulator of epithelial integrity. The peptide is linked to gut barrier support and to the communication between the nervous system and the intestinal tract. This matches the “intestinal” part of its name, but the sources make clear that its role is broader than digestion alone.

Older human work in the provided sources also connects VIP to gastrointestinal physiology. The PMC study on VIP in humans reported infusion-related effects on pancreatic juice secretion, which fits with its history as a gut-active peptide.

Airway and pulmonary tone

The respiratory system appears strongly in the research. One source calls VIP the primary endogenous bronchodilator and pulmonary vasodilator in the lungs. It says VIP is produced by non-adrenergic non-cholinergic neurons and that VIP-deficient states are associated with pulmonary arterial hypertension and airway hyperresponsiveness.

Another research source from 2026 on neuroimmune control of the lung points to continuing interest in how sensory neurons shape lung immunity. While that paper is broader than VIP alone, it fits the overall picture of the lung as a site where neural and immune signaling overlap.

Vascular tone

The “vasoactive” part of VIP’s name refers to blood vessel effects. The materials note that VIP has vasodilatory actions and can affect blood pressure. In the human infusion study, higher doses increased pulse rate and blood pressure amplitude. In other source material, VIP is described as a pulmonary vasodilator and a regulator of vascular smooth muscle.

These vascular effects help explain why VIP is described as a neurovascular peptide, not just a gut peptide.

Circadian and Neuroendocrine Roles

VIP is also linked to the brain and the body clock. One source says VIP produced by neurons in the suprachiasmatic nucleus helps regulate circadian rhythm entrainment and normal sleep-wake cycle maintenance. Another says VIP signaling in the hypothalamus is part of the broader autonomic and neuroendocrine system.

This matters because the body clock affects many other processes, including immune activity and sleep timing. The provided materials do not claim that VIP alone controls these systems. They do show that VIP is one of the signals involved.

The neuroendocrine angle also appears in the source that says VIP supports MSH production through hypothalamic POMC processing. That places VIP upstream of another regulatory pathway discussed in chronic inflammatory contexts.

A peptide with multiple channels

VIP is presented in the research as a peptide that can influence brain signaling, immune tone, and peripheral tissue function at the same time. That combination is why it is often described as a master regulator or pleiotropic molecule.

For another endogenous peptide with brain-linked signaling, see Humanin. For a tissue-repair peptide often discussed alongside endogenous signaling molecules, see GHK.

Low VIP States and Chronic Inflammatory Illness

Several provided sources focus on reduced VIP signaling in chronic inflammatory settings. The strongest example is chronic inflammatory response syndrome, or CIRS, linked to water-damaged buildings. One source says that in three case series with a combined sample of 1,829 patients, VIP deficiency occurred in 98% of patients, while less than 10% of controls showed that deficiency.

The same source says these data were consistent with nearly 5,000 other CIRS-WDB patients and 850 control patients documented in a single clinical practice. Those numbers are specific and central to the source’s argument. The source frames VIP deficiency as a common marker in that population.

Another clinic reference says low VIP signaling is associated with chronic inflammatory illness, gut permeability, immune dysregulation, and neurologic symptoms. These claims are presented as part of an integrative or functional medicine view of VIP.

How to read these reports

The research does not establish VIP deficiency as a universal cause of chronic illness. It does show that some investigators and clinics consider VIP status relevant in certain inflammatory syndromes. The strongest numeric claim in the bundle is the 98% deficiency rate in the CIRS case series. That is a notable finding, but it applies to that reported population, not to everyone.

The human infusion study also shows that VIP has measurable physiologic activity at low doses. In that study, doses of 0.6, 1.3, and 3.3 pmol/kg/min caused clear changes in circulating VIP and some physiologic responses. This supports the idea that VIP is biologically active, even if its normal role is mainly local rather than hormonal.

What the Research Says VIP Is Not

It is important not to overstate VIP. One human study in the source bundle specifically said the data did not support a role for VIP as a circulating hormone under physiological conditions. That is a useful limit. VIP is active, but it should not be reduced to a simple blood-borne hormone story.

The research also does not show that VIP is a cure-all. The language in the sources is broad and sometimes strong, but the data are still context-dependent. VIP seems to matter most as a regulator inside tightly linked systems: nervous, immune, gut, pulmonary, and vascular.

That is a more careful and useful way to think about it. VIP is a messenger with wide reach, but not every condition involving inflammation or the gut can be traced to it.

FAQ

What is VIP in simple terms?

VIP is a natural 28-amino-acid peptide that helps cells communicate. The research links it to immune balance, gut function, airway tone, blood vessel control, and circadian signaling.

Why is VIP called a “master regulator”?

The phrase comes from its wide effects across several systems. VIP acts through VPAC1 and VPAC2 receptors found in the brain, lungs, gut, immune cells, pituitary gland, and blood vessels.

What does VIP do to inflammation?

The source material says VIP lowers pro-inflammatory signals such as TNF-alpha, IL-6, and IL-12, while increasing IL-10. It is also described as supporting regulatory T cells and reducing excessive Th1 and Th17 activity.

Is VIP important in the lungs?

Yes. The research describes VIP as a primary endogenous bronchodilator and pulmonary vasodilator. It also links VIP-deficient states with pulmonary arterial hypertension and airway hyperresponsiveness.

What does the research say about low VIP?

In the materials provided, low VIP signaling is linked to chronic inflammatory illness, gut permeability, immune dysregulation, and neurologic symptoms. In one CIRS case series of 1,829 patients, VIP deficiency was reported in 98% of patients and in less than 10% of controls.